17 Amendments of Thomas ULMER related to 2010/2153(INI)
Amendment 11 #
Motion for a resolution
Recital A
Recital A
A. whereas the national and international health authorities, including the WHO, were aware as early as May 2009 that the H1N1 influenza was not virulent, with this moderate virulence beinghaving since been confirmed by the very low mortality rate observed as a result of this influenza ‘pandemic’ in comparison with the officially recognised figures for seasonal influenza,
Amendment 19 #
Motion for a resolution
Recital B
Recital B
B. whereas the criteria for defining a ‘pandemic’, as adopted by the WHO in 2009, andre based solely on the propagation of the virus while discounting the severity of the infection, distorted the meaning of the word ‘pandemic’ and triggered a false alarm worldwide, with that alarmism giving rise to inappropriate public health decisions and a disproportionate response among the public and administrations of the European Union and its Member States,
Amendment 32 #
Motion for a resolution
Recital C
Recital C
C. whereas the exaggerated costs arising from the management of this crisis in the Member States are primarily a direct consequence of the EU’s lack of independence and critical acumen in relation to the risk evaluation concould perhaps have been reducted by the WHO,
Amendment 41 #
Motion for a resolution
Recital E
Recital E
Amendment 53 #
Motion for a resolution
Recital F
Recital F
F. whereas the differing recommendations made within the EU and the Member States on the subject of the priority groups targeted for vaccination illustrate the huge uncertainties surrounding the evaluation of the H1N1 vaccines recommenddiffered,
Amendment 54 #
Motion for a resolution
Recital F a (new)
Recital F a (new)
Fa. whereas assessments of the vaccines differed,
Amendment 58 #
Motion for a resolution
Recital G
Recital G
Amendment 61 #
Motion for a resolution
Recital I
Recital I
Amendment 71 #
Motion for a resolution
Recital J
Recital J
J. whereas information has been garnered by various parliamentary committees and evaluation missions conductedby means of evaluation measures carried out in the EU Member States on the action taken to combat H1N1 influenza,
Amendment 78 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Calls for the prevention plans established in the EU and its Member States to be revised to make them sufficiently autonomous and flexible toflexible so that they can be adapted as swiftly as possible and on a case by case basis to the actual risk, based not least on the latest scientific information available;
Amendment 93 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Takes the view that the powers of the European Centre for Disease Prevention and Control (ECDC) should be reinforced so that the EU has its own means of assessing the severity of infection risk, by establishing, if necessary, its own health alert scale independent of inter cooperation with national organisations such as the WHO;
Amendment 96 #
Motion for a resolution
Paragraph 3
Paragraph 3
Amendment 107 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls for immediate clarifications on the effectiveness of the influenza vaccination strategies recommended in the EU, given the weight of evidence casting doubt on their effectiveness, the absence of reliable data guaranteeing that effectiveness and the lingering uncertainties surrounding their benefit-risk profile;
Amendment 129 #
Motion for a resolution
Paragraph 8
Paragraph 8
Amendment 138 #
Motion for a resolution
Paragraph 9
Paragraph 9
Amendment 159 #
Motion for a resolution
Paragraph 11
Paragraph 11
11. Demands precise definition of the roles, duties, remits, limits, relations and responsibilities of the Commission, the ECDC, the EMA and the Member States and also of more informal entities such as the Health Security Committee, the HEOF and the ‘public health’ group, composed of senior officials able to intervene in the decision-making process regarding the management of a health crisis;
Amendment 165 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Expresses its approval of the introduction of a procedure enabling the Member States to make group purchases of anti-viral vaccines and medicinal products on a voluntary basis where the positive benefit-risk profile of their preventive/therapeutic effect is clearly demonstrated and indisputable, in order to obtain, for a given product, advantageous rates approaching its cost price;